Production of bioactive, SUMO-modified, and native-like TNF-α of the rhesus monkey, Macaca mulatta, in Escherichia coli

Applied Microbiology and Biotechnology

Volumn 93, Issue 6, 2012, Pages 2345-2355

  Jia, Dianlong ^a   Yang, Hao ^a   Wan, Lin ^a   Cheng, Jingqiu ^a   Lu, Xiaofeng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Autoimmune disease; Rhesus monkey; Small ubiquitin like modifier; Tumor necrosis factor

Indexed keywords

AUTOIMMUNE DISEASE; BACTERIAL CULTURES; E. COLI; FUSION PROTEINS; FUSION SYSTEMS; HUMAN CANCER CELLS; IN-VITRO; INSOLUBLE PROTEINS; LIVER CANCER CELLS; NEUTRALIZING AGENTS; RHESUS MONKEY; SMALL UBIQUITIN-LIKE MODIFIERS; SOLUBLE FRACTION; SOLUBLE RECEPTOR; SYNTHETIC GENES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTORS;

BIODEGRADATION; CELL CULTURE; GENE ENCODING; GLYCOPROTEINS; MACROPHAGES; OLIGOMERS;

ESCHERICHIA COLI;

BACTERIAL PROTEIN; HYBRID PROTEIN; RECOMBINANT PROTEIN; SUMO PROTEIN; SYNTHETIC DNA; TUMOR NECROSIS FACTOR ALPHA; SUMO 1 PROTEIN;

ANTIBODY; BIOACTIVITY; BIOTECHNOLOGY; CANCER; FECAL COLIFORM; GENE EXPRESSION; HORMONE; NEUTRALIZATION; PATHOGENICITY; PRIMATE; PROTEIN; PUBLIC HEALTH;

APOPTOSIS; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BREAST CANCER; CANCER CELL; CELL CULTURE; CYTOTOXICITY; ESCHERICHIA COLI; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER CANCER; LUNG CANCER; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; RHESUS MONKEY; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; GENE EXPRESSION; GENETICS; MACACA MULATTA; METABOLISM; MOUSE; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MACACA MULATTA;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; MACACA MULATTA; MICE; RECOMBINANT FUSION PROTEINS; SUMO-1 PROTEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862296224     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-011-3794-1     Document Type: Article

References (36)

1. Altan ZM, Denis D, Kagan D, Grund EM, Palmer SS, Nataraja SG (2010) A long-acting tumor necrosis factor alpha-binding protein demonstrates activity in both in vitro and in vivo models of endometriosis. J Pharmacol Exp Ther 334:460-466
2. Anderson G, Nakada MT, DeWitte M (2004) Tumor necrosis factor alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4:314-320
3. Bertazza L, Mocellin S (2010) The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem 17:3337-3352
4. Butt TR, Edavettal SC, Hall JP, Mattern MR (2005) SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif 43:1-9
5. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72:3666-3670
6. Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R (2011) Targeted drug delivery and penetration into solid tumors. Med Res Rev. doi:10.1002/med.20238
7. Esposito E, Cuzzocrea S (2009) TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 16:3152-3167
8. Fonda I, Kenig M, Gaberc-Porekar V, Pristovaek P, Menart V (2002) Attachment of histidine tags to recombinant tumor necrosis factor-alpha drastically changes its properties. Sci World J 2:1312-1325
9. Garcia-Valladares I, Cuchacovich R, Espinoza LR (2011) Comparative assessment of biologics in treatment of psoriasis: Drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther 5:41-49
10. Gerspach J, Pfizenmaier K,Wajant H (2009) Improving TNF as a cancer therapeutic: Tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors 35:364-372
11. Giersberg M, Floss DM, Kipriyanov S, Conrad U, Scheller J (2010) Covalent dimerization of camelidae anti-human TNF-alpha single domain antibodies by the constant kappa light chain domain improves neutralizing activity. Biotechnol Bioeng 106:161-166
12. Grünhagen DJ, de Wilt JH, van Geel AN, Verhoef C, Eggermont AM (2009) Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res 179:257-270
13. Hoffmann A, Müller MQ, Gloser M, Sinz A, Rudolph R, Pfeifer S (2010) Recombinant production of bioactive human TNF-alpha by SUMO-fusion system-high yields from shake-flask culture. Protein Expr Purif 72:238-243
14. Hundsberger H, Verin A, Wiesner C, Pflüger M, Dulebo A, Schütt W, Lasters I, Männel DN, Wendel A, Lucas R (2008) TNF: A moonlighting protein at the interface between cancer and infection. Front Biosci 13:5374-5386
15. Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kühnle M, Gerspach J, Sterns T, Shnyder SD, Gill JH,Männel DN, Pfizenmaier K, Scheurich P (2008) Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 180:8176-8183
16. Lejeune FJ, Liénard D, Matter M, Rüegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6
17. Lyu M, Kurzrock R, Rosenblum MG (2008) The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. Biochem Pharmacol 75:836-846
18. Messerschmidt SK,Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K, Landfester K, Kontermann RE (2009) Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release 137:69-77
19. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV (1984) Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312:724-729
20. Rege K, Patel SJ, Megeed Z, Yarmush ML (2007) Amphipathic peptidebased fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res 67:6368-6375
21. Rossi CR, Russano F, Mocellin S, Chiarion-Sileni V, Foletto M, Pilati P, Campana LG, Zanon A, Picchi GF, Lise M, Nitti D (2008) TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: A pilot trial. Ann Surg Oncol 15:1218-1223
22. Rubin DT, Panaccione R, Chao J, Robinson AM (2011) A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin 27:1803-1813
23. Sethi G, Sung B, Kunnumakkara AB, Aggarwal BB (2009) Targeting TNF for treatment of cancer and autoimmunity. Adv Exp Med Biol 647:37-51
24. Shoji Y, Inoue Y, Sugisawa H, Itou T, Endo T, Sakai T (2001) Molecular cloning and functional characterization of bottlenose dolphin (Tursiops truncatus) tumor necrosis factor alpha. Vet Immunol Immunopathol 82:183-192
25. Smith RA, Baglioni C (1987) The active form of tumor necrosis factor is a trimer. J Biol Chem 262:6951-6954
26. Szlosarek P, Charles KA, Balkwill FR (2006) Tumour necrosis factoralpha as a tumour promoter. Eur J Cancer 42:745-750
27. Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S (2008) Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 24:193-203
28. Taylor PC, Feldmann M (2009) Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5:578-582
29. Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, Stuart RC, Wright N, Harrison R, Jankowski JA (2002) Tumour necrosis factor-alpha in Barrett's oesophagus: A potential novel mechanism of action. Oncogene 21:6071-6081
30. van Horssen R, Ten Hagen TL, Eggermont AM (2006) TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 11:397-408
31. Vierboom MP, Jonker M, Tak PP, Hart BA (2007) Preclinical models of arthritic disease in non-human primates. Drug Discov Today 12:327-335
32. Villinger F, Bostik P, Mayne A, King CL, Genain CP, Weiss WR, Ansari AA (2001) Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules. Immunogenetics 53:315-328
33. Wallis RS (2008) Tumor necrosis factor antagonists: Structure, function, and tuberculosis risks. Lancet Infect Dis 8:601-611
34. Wang H, Chen K, Cai W, Li Z, He L, Kashefi A, Chen X (2008) Integrin-targeted imaging and therapy with nRGD4C-TNF fusion protein. Mol Cancer Ther 7:1044-1053
35. Wedlock DN, Aldwell FE, Buddle BM (1996) Molecular cloning and characterization of tumor necrosis factor alpha (TNF-alpha) from the Australian common brushtail possum, Trichosurus vulpecula. Immunol Cell Biol 74:151-158
36. Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB (2009) Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther 8:1906-1915